Beyond Thinking
Welcome to Beyond Blue’s Thought Leadership Hub, where we highlight complex concepts with clarity and showcase our commitment to delivering excellence with ease. Explore our insights, discover innovative perspectives and join us on a journey to navigate the intricate with confidence.
Cut the Clutter: How quantitative testing drives message precision
Too many messages, too little time. Brand teams often face a conveyor belt of messages and visuals, each one rolling past with its own merit, creative direction, and strategic grounding. But HCPs are time-poor, and in both testing and real-life sales, we have only...
Celebrating Culture and Connection: Manchester meetup
Author: Kelly Shipley, Head of Talent On 1st October, we did something special. We brought our global team together in person for the start of our annual networking and connection day. We met at our city centre venue in Manchester to connect, share, and identify...
ESMO 2025 Reflections
Four potentially practice-changing bladder cancer papers This year’s ESMO congress delivered a wealth of impactful data across the bladder cancer spectrum, from muscle-invasive to metastatic disease. Here are four standout studies with potential to reshape clinical...
When the Gates Stay Closed: Strategic guidance on what to do when launch delays hit
Author: Alex Hunt, Research Manager, Beyond Blue Strategy In the recent article from our Beyond Neurology team, we traced the journey of BTK inhibitors (BTKi) in Multiple Sclerosis (MS), a story marked by scientific promise, high expectations, and a few sharp turns...
CoLoop vs Professional Translation: A pragmatic comparison for researchers
Author: Mike Pepp, Senior Commercial Consultant, Beyond Blue Like many agencies, we are always striving to use new technologies that reduce time to insight – balancing this with the need to have confidence that the quality of our learnings and insights is maintained...
ESMO 2025: Ones to watch
Explore the headlines set to surface at ESMO 2025. ADCs make their move into early-stage disease Drugs like Enhertu and Padcev, already headline-makers in metastatic disease, are now making waves in early-stage settings. DESTINY-Breast05, DESTINY-Breast11, and...
Spotlight on BTK Inhibitors in MS
In recent years, interest in BTK inhibitors (BTKi) for MS has surged, with hopes that they could offer a new way to tackle the underlying drivers of the disease. But the journey, so far, has been a rollercoaster, and the delayed FDA decision on tolebrutinib marks the...
Smarter Tools, Smarter Care: How Innovation is Transforming Prostate Cancer
From early detection to advanced therapy, prostate cancer care is being reshaped by smarter tools that provide deeper insight and more precise interventions. These advances are enabling clinicians to act sooner, tailor treatment more accurately, and expand options for...
The Power of Words: In sickness and in health
Author: Sam Hope, CEO, Beyond Blue Why is it that some people will happily stick to collagen powders and herbal elixirs but skip life-saving medication? This puzzling question became the spark for our self-funded study. Watching my own mother consistently and...
